Arrowstreet Capital
MYGN icon

Arrowstreet Capital’s Myriad Genetics MYGN Stock Holding History

Arrowstreet Capital’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.47M Buy
782,765
+578,157
+283% +$2.62M ﹤0.01% 1321
2026
Q1 		$921K Buy
+204,608
New +$1.07M ﹤0.01% 1571
2025
Q1 		– Sell
-153,062
Closed -$2.1M – 1941
2024
Q4 		$2.1M Sell
153,062
-24,519
-14% -$452K ﹤0.01% 1265
2024
Q3 		$4.86M Buy
+177,581
New +$4.81M ﹤0.01% 966
2021
Q1 		– Sell
-18,264
Closed -$361K – 2426
2020
Q4 		$361K Sell
18,264
-515,954
-97% -$8.33M ﹤0.01% 2082
2020
Q3 		$6.97M Sell
534,218
-308,782
-37% -$3.91M 0.01% 995
2020
Q2 		$9.56M Buy
+843,000
New +$12M 0.02% 791
2020
Q1 		– Sell
-22,900
Closed -$624K – 2022
2019
Q4 		$624K Buy
+22,900
New +$630K ﹤0.01% 1449
2018
Q4 		– Sell
-114,429
Closed -$5.26M – 1447
2018
Q3 		$5.26M Buy
114,429
+98,429
+615% +$4.38M 0.01% 500
2018
Q2 		$598K Sell
16,000
-12,248
-43% -$414K ﹤0.01% 887
2018
Q1 		$835K Sell
28,248
-29,252
-51% -$990K ﹤0.01% 897
2017
Q4 		$1.98M Buy
+57,500
New +$1.94M ﹤0.01% 824
2016
Q2 		– Sell
-49,657
Closed -$1.86M – 1443
2016
Q1 		$1.86M Buy
+49,657
New +$1.87M 0.01% 836
2015
Q3 		– Sell
-66,829
Closed -$2.27M – 1443
2015
Q2 		$2.27M Buy
+66,829
New +$2.27M 0.01% 606
2014
Q1 		– Sell
-166,872
Closed -$3.5M – 1261
2013
Q4 		$3.5M Sell
166,872
-17,307
-9% -$438K 0.02% 530
2013
Q3 		$4.33M Buy
184,179
+102,430
+125% +$2.91M 0.03% 406
2013
Q2 		$2.2M Buy
+81,749
New +$2.37M 0.02% 443

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital's MYGN Position: Q2 2026 in Review

Arrowstreet Capital increased its Myriad Genetics (MYGN) stake by 283% in Q2 2026, buying an estimated $2.62M and bringing the position to 782,765 shares worth $4.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1321.

Arrowstreet Capital first reported a position in MYGN in Q2 2013 and has held it in 17 quarters since. The position peaked at $9.56M in Q2 2020. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Arrowstreet Capital held 782,765 shares of Myriad Genetics worth $4.47M as of Q2 2026.
  • Arrowstreet Capital bought 578,157 Myriad Genetics shares in Q2 2026, an estimated $2.62M.
  • Myriad Genetics made up ﹤0.01% of Arrowstreet Capital's portfolio in Q2 2026, its #1321 holding.
  • Arrowstreet Capital first reported a position in Myriad Genetics in Q2 2013 and has held it in 17 quarters since.
  • Arrowstreet Capital's Myriad Genetics position peaked at $9.56M in Q2 2020.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.